tiprankstipranks
Xencor Inc. (CH:XE9)
NASDAQ:XE9
Switzerland Market
XE9
Xencor
RESEARCH TOOLSreports

Xencor (XE9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

XE9 Analyst Ratings

Strong Buy
11Ratings
Strong Buy
9 Buy
2 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Xencor
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XE9 Stock 12 Month Forecast

Average Price Target

$19.32
Based on 11 Wall Street analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $19.32 with a high forecast of $30.21 and a low forecast of $10.34. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$30.21Average Price Target$19.32Lowest Price Target$10.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:XE9
Etzer Darout
Barclays
Barclays
CHF21.47
Buy
―
Reiterated
06/16/26
Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (NYSE: EW), Xencor (NASDAQ: XNCR) and Definitive Healthcare Corp (NASDAQ: DH)
Bank of America Securities Analyst forecast on CH:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF13.52
Hold
―
Reiterated
05/13/26
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR)
TD Cowen Analyst forecast on CH:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (NYSE: DNA), Xencor (NASDAQ: XNCR) and Alto Neuroscience, Inc. (NYSE: ANRO)
J.P. Morgan Analyst forecast on CH:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF10.34→CHF11.13
Hold
―
Assigned
05/11/26
Xencor price target raised to $14 from $13 at JPMorganXencor price target raised to $14 from $13 at JPMorgan
Piper Sandler Analyst forecast on CH:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF26.24
Buy
―
Reiterated
05/08/26
Piper Sandler Reaffirms Their Buy Rating on Xencor (XNCR)
Wells Fargo Analyst forecast on CH:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF21.47
Buy
―
Reiterated
05/07/26
Xencor (XNCR) Receives a Buy from Wells Fargo
Wedbush Analyst forecast on CH:XE9
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF20.67
Buy
―
Reiterated
05/07/26
Wedbush Remains a Buy on Xencor (XNCR)
Truist Financial Analyst forecast on CH:XE9
Gregory Renza
Truist Financial
Truist Financial
CHF23.06
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), DENTSPLY SIRONA (NASDAQ: XRAY) and Neurocrine (NASDAQ: NBIX)
Canaccord Genuity Analyst forecast on CH:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
CHF30.21
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Oscar Health (NYSE: OSCR) and REPRO-MED Systems (NASDAQ: KRMD)
William Blair Analyst forecast on CH:XE9
Matt Phipps
William Blair
William Blair
CHF10.34
Buy
―
Reiterated
05/06/26
Buy Rating on Xencor as TL1A Franchise Data and Upcoming Phase IIb Catalyst Support Upside Potential
RBC Capital Analyst forecast on CH:XE9
Leonid Timashev
RBC Capital
RBC Capital
CHF15.11
Buy
―
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Rhythm Pharmaceuticals (RYTM)
Cantor Fitzgerald Analyst forecast on CH:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF34.19
Buy
―
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Xencor (NASDAQ: XNCR) and Pennant Group (NASDAQ: PNTG)
Roth MKM Analyst forecast on CH:XE9
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
CHF4.77
Sell
―
Initiated
09/17/25
Xencor (XNCR) Receives a Sell from Roth MKM
Raymond James Analyst forecast on CH:XE9
Sean McCutcheon
Raymond James
Raymond James
CHF31.8
Buy
―
Reiterated
08/07/25
Leerink Partners Analyst forecast on CH:XE9
Jonathan Chang
Leerink Partners
Leerink Partners
CHF21.47
Buy
―
Reiterated
08/07/25
Xencor (XNCR) Receives a Buy from Leerink Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:XE9
Etzer Darout
Barclays
Barclays
CHF21.47
Buy
―
Reiterated
06/16/26
Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (NYSE: EW), Xencor (NASDAQ: XNCR) and Definitive Healthcare Corp (NASDAQ: DH)
Bank of America Securities Analyst forecast on CH:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF13.52
Hold
―
Reiterated
05/13/26
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR)
TD Cowen Analyst forecast on CH:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (NYSE: DNA), Xencor (NASDAQ: XNCR) and Alto Neuroscience, Inc. (NYSE: ANRO)
J.P. Morgan Analyst forecast on CH:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF10.34→CHF11.13
Hold
―
Assigned
05/11/26
Xencor price target raised to $14 from $13 at JPMorganXencor price target raised to $14 from $13 at JPMorgan
Piper Sandler Analyst forecast on CH:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF26.24
Buy
―
Reiterated
05/08/26
Piper Sandler Reaffirms Their Buy Rating on Xencor (XNCR)
Wells Fargo Analyst forecast on CH:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF21.47
Buy
―
Reiterated
05/07/26
Xencor (XNCR) Receives a Buy from Wells Fargo
Wedbush Analyst forecast on CH:XE9
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF20.67
Buy
―
Reiterated
05/07/26
Wedbush Remains a Buy on Xencor (XNCR)
Truist Financial Analyst forecast on CH:XE9
Gregory Renza
Truist Financial
Truist Financial
CHF23.06
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), DENTSPLY SIRONA (NASDAQ: XRAY) and Neurocrine (NASDAQ: NBIX)
Canaccord Genuity Analyst forecast on CH:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
CHF30.21
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Oscar Health (NYSE: OSCR) and REPRO-MED Systems (NASDAQ: KRMD)
William Blair Analyst forecast on CH:XE9
Matt Phipps
William Blair
William Blair
CHF10.34
Buy
―
Reiterated
05/06/26
Buy Rating on Xencor as TL1A Franchise Data and Upcoming Phase IIb Catalyst Support Upside Potential
RBC Capital Analyst forecast on CH:XE9
Leonid Timashev
RBC Capital
RBC Capital
CHF15.11
Buy
―
Reiterated
05/05/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Rhythm Pharmaceuticals (RYTM)
Cantor Fitzgerald Analyst forecast on CH:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
CHF34.19
Buy
―
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Xencor (NASDAQ: XNCR) and Pennant Group (NASDAQ: PNTG)
Roth MKM Analyst forecast on CH:XE9
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
CHF4.77
Sell
―
Initiated
09/17/25
Xencor (XNCR) Receives a Sell from Roth MKM
Raymond James Analyst forecast on CH:XE9
Sean McCutcheon
Raymond James
Raymond James
CHF31.8
Buy
―
Reiterated
08/07/25
Leerink Partners Analyst forecast on CH:XE9
Jonathan Chang
Leerink Partners
Leerink Partners
CHF21.47
Buy
―
Reiterated
08/07/25
Xencor (XNCR) Receives a Buy from Leerink Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xencor

3 Months
David NierengartenWedbush
Success Rate
6/11 ratings generated profit
55%
Average Return
+14.36%
Copying David Nierengarten's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +14.36% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
4/11 ratings generated profit
36%
Average Return
-4.61%
Copying John Newman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -4.61% per trade.
2 Years
Edward TenthoffPiper Sandler
Success Rate
4/12 ratings generated profit
33%
Average Return
-2.02%
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -2.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XE9 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
9
10
9
9
7
Buy
6
7
5
5
3
Hold
2
3
2
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
20
16
18
13
In the current month, XE9 has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. XE9 average Analyst price target in the past 3 months is 19.32.
Each month's total comprises the sum of three months' worth of ratings.

XE9 Financial Forecast

XE9 Earnings Forecast

Next quarter’s earnings estimate for XE9 is -$0.64 with a range of -$0.86 to -$0.32. The previous quarter’s EPS was -$1.36. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for XE9 is -$0.64 with a range of -$0.86 to -$0.32. The previous quarter’s EPS was -$1.36. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Sales Forecast

Next quarter’s sales forecast for XE9 is $14.49M with a range of $2.26M to $31.80M. The previous quarter’s sales results were $3.59M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s sales forecast for XE9 is $14.49M with a range of $2.26M to $31.80M. The previous quarter’s sales results were $3.59M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Stock Forecast FAQ

What is CH:XE9’s average 12-month price target, according to analysts?
Based on analyst ratings, Xencor Inc.’s 12-month average price target is 19.32.
    What is CH:XE9’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:XE9, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Xencor Inc. a Buy, Sell or Hold?
        Xencor Inc. has a consensus rating of Strong Buy, which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Xencor Inc.’s share price target?
          The average share price target for Xencor Inc. is 19.32. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $30.21 ,and the lowest forecast is $10.34. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Xencor Inc.?
            Xencor Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
              How can I buy shares of Xencor Inc.?
              To buy shares of CH:XE9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.